Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 MicroRNA immunomodulating therapeutics.

Literature DB >> 31945151

MicroRNA immunomodulating therapeutics.

Sara E Meyer¹.
1. Thomas Jefferson University.

Abstract

Mesh：

Substances：
MicroRNAs
NF-kappa B

Year: 2020 PMID： 31945151 PMCID： PMC6966931 DOI： 10.1182/blood.2019004106

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

9 in total

1. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies.

Authors: Jimmy L Zhao; Dinesh S Rao; Mark P Boldin; Konstantin D Taganov; Ryan M O'Connell; David Baltimore
Journal: Proc Natl Acad Sci U S A Date: 2011-05-16 Impact factor: 11.205

2. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.

Authors: Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore
Journal: Proc Natl Acad Sci U S A Date: 2006-08-02 Impact factor: 11.205

3. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.

Authors: Margherita Norelli; Barbara Camisa; Giulia Barbiera; Laura Falcone; Ayurzana Purevdorj; Marco Genua; Francesca Sanvito; Maurilio Ponzoni; Claudio Doglioni; Patrizia Cristofori; Catia Traversari; Claudio Bordignon; Fabio Ciceri; Renato Ostuni; Chiara Bonini; Monica Casucci; Attilio Bondanza
Journal: Nat Med Date: 2018-05-28 Impact factor: 53.440

4. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.

Authors: Theodoros Giavridis; Sjoukje J C van der Stegen; Justin Eyquem; Mohamad Hamieh; Alessandra Piersigilli; Michel Sadelain
Journal: Nat Med Date: 2018-05-28 Impact factor: 53.440

5. Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo.

Authors: Yu-Lin Su; Xiuli Wang; Mati Mann; Tomasz P Adamus; Dongfang Wang; Dayson F Moreira; Zhuoran Zhang; Ching Ouyang; Xin He; Bin Zhang; Piotr M Swiderski; Stephen J Forman; David Baltimore; Ling Li; Guido Marcucci; Mark P Boldin; Marcin Kortylewski
Journal: Blood Date: 2020-01-16 Impact factor: 22.113

6. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.

Authors: Qifang Zhang; Dewan Md Sakib Hossain; Sergey Nechaev; Anna Kozlowska; Wang Zhang; Yong Liu; Claudia M Kowolik; Piotr Swiderski; John J Rossi; Stephen Forman; Sumanta Pal; Ravi Bhatia; Andrew Raubitschek; Hua Yu; Marcin Kortylewski
Journal: Blood Date: 2013-01-03 Impact factor: 22.113

7. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Authors: Daniel T Starczynowski; Florian Kuchenbauer; Bob Argiropoulos; Sandy Sung; Ryan Morin; Andrew Muranyi; Martin Hirst; Donna Hogge; Marco Marra; Richard A Wells; Rena Buckstein; Wan Lam; R Keith Humphries; Aly Karsan
Journal: Nat Med Date: 2009-11-08 Impact factor: 53.440

8. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice.

Authors: Mark P Boldin; Konstantin D Taganov; Dinesh S Rao; Lili Yang; Jimmy L Zhao; Manorama Kalwani; Yvette Garcia-Flores; Mui Luong; Asli Devrekanli; Jessica Xu; Guizhen Sun; Jia Tay; Peter S Linsley; David Baltimore
Journal: J Exp Med Date: 2011-05-09 Impact factor: 14.307

9. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

Authors: Marcin Kortylewski; Piotr Swiderski; Andreas Herrmann; Lin Wang; Claudia Kowolik; Maciej Kujawski; Heehyoung Lee; Anna Scuto; Yong Liu; Chunmei Yang; Jiehui Deng; Harris S Soifer; Andrew Raubitschek; Stephen Forman; John J Rossi; Drew M Pardoll; Richard Jove; Hua Yu
Journal: Nat Biotechnol Date: 2009-09-13 Impact factor: 54.908